MedTrace Logo

Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.

NCT00611026 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2417

Last updated 2011-02-02

Study results available
· View outcomes & findings →

Summary

To evaluate the efficacy and safety of fesoterodine in comparison to tolterodine and placebo for overactive bladder

Conditions

Interventions

DRUG

Tolterodine ER

The tolterodine treatment will be 4 mg once daily(QD) for 12 weeks.

DRUG

Placebo

Placebo treatment will be once daily(QD) for 12 weeks.

DRUG

Fesoterodine

The fesoterodine treatment will start with 4 mg once daily(QD) for 1 week followed by a forced dose-escalation to 8mg once daily(QD) for 11 weeks.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2009-10-31
Completion
2009-10-31

Countries

  • United States
  • Brazil
  • Bulgaria
  • Canada
  • Colombia
  • Costa Rica
  • Estonia
  • Germany
  • Greece
  • Hungary
  • India
  • Ireland
  • Latvia
  • Lithuania
  • Malaysia
  • Poland
  • Romania
  • Russia
  • Singapore
  • Slovakia
  • South Africa
  • South Korea
  • Spain
  • Sweden
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00611026 on ClinicalTrials.gov